Analyst Updates on Crinetics Pharmaceuticals Following PALSONIFY Rollout
Crinetics Pharmaceuticals (NASDAQ:CRNX) has attracted analyst attention due to its progress with the rollout of PALSONIFY and ongoing clinical trials. Oppenheimer lowered its price target from $87 to $84 while maintaining an 'Outperform' rating, citing strong enrollment in Phase 3 studies and positive revenue growth. Citizens also reduced their price target but kept a similar outlook.
Tickers: $CRNX
Topics: Clinical Trials Pharmaceuticals Revenue Growth Stock Analysis